92. Mushrooms and Mania: Differentiating Psilocybin-Induced Mania From First-Break Bipolar Mania - Tyler D. McGehee; Nicole Lacap; Adeel Iqbal; Alan M. Langlieb (Journal of the Academy of Consultation-Liaison Psychiatry, 2025)

CNSC-36. PSILOCYBIN INDUCES SUSTAINED GLIOMA GROWTH THROUGH SEROTONERGIC AND TRKB PATHWAYS - Richard Drexler; Belgin Yalçın; Rebecca Mancusi; Abigail Rogers; Kiarash Shamardani; Pamelyn J. Woo; Alexandre Ravel; Yahaya A Yabo; Carlos Alberto Oliveira de Biagi-Junior; Costanza Lo Cascio; Robert C. Malenka; Boris D. Heifets; et al. (Neuro-Oncology, 2025)

Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope? - Thomas Zandonai; Sofia Venturini; Ornella Corazza (Performance Enhancement & Health, 2025)

[Acceptance of psilocybin-assisted therapy in German-speaking countries]. - Hartter N; Däumichen M; Schmidt C; Wolff M; Gründer G; Jungaberle H (Der Nervenarzt, 2025)

Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis. - Swieczkowski D; Kwaśny A; Pruc M; Gaca Z; Szarpak L; Cubała WJ (International journal of psychiatry in medicine, 2025)

Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View. - Lashgari NA; Khalaji M; Rana P; Badrabadi F; Rahnama M; Nasoori H; Momeni Roudsari N; Khosravi Nia MM; Shafaroodi H (Molecular neurobiology, 2025)

Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India. - Joga R; Yerram S; Patnam JD; Choudhary KK; Varpe P; Raghuvanshi RS; Srivastava S (Health policy (Amsterdam, Netherlands), 2025)

The emotional architecture of the psychedelic brain. - Moujaes F; Rieser NM; Belinger L; Herdener M; Zahid Z; Preller KH (Trends in cognitive sciences, 2025)

Psilocybin-assisted psychotherapy, combined antipsychotic and antidepressant treatment for bipolar depression, duration of birth control pill use and risk of depression, handgrip strength and cognitive function, mood disorders in epilepsy, and mental health issues among physicians. - Koenig HG (International journal of psychiatry in medicine, 2025)

The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives. - Rahmani S; Crupi R; Riley AL; Davidson T (Pharmacology, biochemistry, and behavior, 2025)

N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences. - Vohryzek J; Luppi AI; Atasoy S; Deco G; Carhart-Harris RL; Timmermann C; Kringelbach ML (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2025)

Emerging mechanisms of psilocybin-induced neuroplasticity. - Sonda S; Pendin D; Comai S; De Martin S; Manfredi P; Mattarei A (Trends in pharmacological sciences, 2025)

Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain. - Hammo A; Wisser S; Cichon J (Nature neuroscience, 2025)

Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds. - Hosein MM; Reid MJ; Walser S; Charney S; Fonzo GA; Lewis BR; Yaden DB; Suppes T; Cordner ZA; Barrett FS (EClinicalMedicine, 2025)

Psychedelic 5-HT receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function. - Padawer-Curry JA; Krentzman OJ; Kuo CC; Wang X; Bice AR; Nicol GE; Snyder AZ; Siegel JS; McCall JG; Bauer AQ (Nature neuroscience, 2025)

Acute Kidney Failure and Myocarditis Triggered by Magic Mushroom Toxicity in a Patient With Prior Cocaine Exposure. - Oo AP; Tseu S; Ponnusamy A (Cureus, 2025)

Paper spray and direct mushroom spray mass spectrometry methods for the analysis of psycho-neurological disorder toxins - Luo W; Dai Q; van Beek TA; Zuilhof H; Chen B; Chen Z; Salentijn GI. (Food Chemistry, 2025)

Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications - André Leão Dantas; Lara Moreira Jalles Milani; Saulo Gabriel Moreira Falci; João Américo da Silveira; Cristina Pereira Isolan; Lia Dietrich (Caderno Pedagógico, 2025)

“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics - Blake Beaton (Journal of Drug Issues, 2025)

Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin - Washington University School of Medicine (ClinicalTrials.gov, 2025)

Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes. - d'Andrea G; Chiappini S; Ciavoni L; Tucci R; Martino F; Semeraro FM; Di Battista D; Mosca A; Miuli A; Di Carlo F; Russo M; Di Petta G; et al. (Translational psychiatry, 2025)

A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)? - Anna Rose Childress; Ph.D. (ClinicalTrials.gov, 2025)

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial. - Richardson C; Chan C; Macgregor E; Hare C; Hannon B; Black S; Schneider E; Buchman D; Wang S; Rac V; Abrahamyan L; Huszti E; et al. (Pilot and feasibility studies, 2025)

Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence - James J Gattuso; Bilgenur Bezcioglu; Carey Wilson; Kato Havaux; Anthony J. Hannan; Thibault Renoir (Psychedelics., 2025)

Structure-Guided Design of Novel 5-HT Partial Agonists as Psychedelic Analogues with Antidepressant Effects. - Li R; Yan H; Chen Y; Liu Y; Tang L; Yu J; Liu J; Wang H; Wang S; Cheng J (Journal of medicinal chemistry, 2025)

Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report. - Farzin H; Koren B; Ferrier H; Sanders JJ; Garel N (Palliative & supportive care, 2025)

A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder. - Keighley EE; Abo Hamza E; Bedewy DA; Nalla S; Moustafa AA (Healthcare (Basel, Switzerland), 2025)

Psychedelics and time: Exploring altered temporal perception and its implications for consciousness, neuroscience, and therapy - Pu Jiang; Cong Lin; Xiaohui Wang (Psychedelics., 2025)

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults - University of California; Berkeley (ClinicalTrials.gov, 2025)

Is there more to magic mushrooms than psilocybin? - special to C EN Mara Johnson-Groh (C&EN Global Enterprise, 2025)

The THRIVE Model of Psychedelic Integration: A Holistic Framework Bridging Indigenous Knowledge and Evidence-Based Practice - Ashvind N. Singh; Glauber Loures de Assis (Current Treatment Options in Psychiatry, 2025)

Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review - Suspene J; Huet S; Berteina-Raboin S; Benyamina A; Baril P; Morisset-Lopez S; Serreau R. (Preprints.org, 2025)

Psychedelic compounds directly excite 5-HT2A layer V medial prefrontal cortex neurons through 5-HT2A Gq activation - Gabriele M. König; Li-Ming Hsu; Yi-Ting Chiu; Gavin P. Schmitz; Martin MacKinnon; Yen-Yu I. Shih; Bryan L. Roth; Sarah N. Magee; Evi Kostenis; Melissa A. Herman; Mia L. Foglesong (UNC Libraries, 2025)

Structure-GuidedDesign of Novel 5-HT2A Partial Agonists as PsychedelicAnalogues with Antidepressant Effects - Rongyan Li (11403789); Haohan Yan (22432650); Yujin Chen (1412254); Yangyang Liu (807797); Lingjie Tang (9276407); Jing Yu (81085); Junjun Liu (674159); Huan Wang (109286); Sheng Wang (339979); Jianjun Cheng (646595) (Figshare, 2025)

Analysis of Serotonin in Caenorhabditis Elegans Subjected to Micro-Dosing with Psilocybin| Iris Publishers - Douglas B. Craig (Insights in Chemistry and Biochemistry, 2025)

Psilocybin exerts differential effects on social behaviour and inflammation in mice in contexts of activity-based anorexia (ABA) - Shadani S; Greaves E; Andrews ZB; Foldi CJ. (bioRxiv, 2025)

Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment - Sha Jin; H.Y. Wang; Xiaohui Wang (Psychedelics., 2025)

A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer - University of Washington (ClinicalTrials.gov, 2025)

Intravenous Administration of Serotonergic Psychedelics Produce Short-lasting Changes in Sleep-Wake Behavior and High Gamma Functional Connectivity in Rats. - Kolbman N; Huels ER; Nelson A; Summerfield R; Byraju K; Groenhout T; Liu T; Hudetz AG; Vanini G; Pal D (bioRxiv: the preprint server for biology, 2025)

The Research Deficit and Expert Disagreement Regarding Music Selection for Psychedelic Assisted Therapy. - Moskovitz M (ACS pharmacology & translational science, 2025)

Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice. - Razidlo J; Cataldo N; Wenthur CJ (ACS pharmacology & translational science, 2025)

Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study. - Vanessa Zavala Cruz; Lynnette A. Averill; David S. Mathai; James J. Crowley; Muñoz; Josselyn S; Carolyn I. Rodríguez; Jill O. Robinson; Eric A. Storch; Kevin M. Wagner; Amy L. McGuire; Jacey L Anderberg; et al. (UNC Libraries, 2025)

Psychedelics in Practice: Science, Safety, and the Future of Healing - Renee Ireland (The proceedings of sliit international conference on advancements in science and humanities, 2025)

Neurocomputational evidence of sustained Self-Other mergence after psychedelics - Mallaroni P; Mason NL; Preller KH; Razi A; Ereira S; Ramaekers JG. (medRxiv, 2025)

A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine - Kevin Murnane (ClinicalTrials.gov, 2025)

Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ) - Centre Hospitalier St Anne (ClinicalTrials.gov, 2025)

Towards Novel Antidepressant Strategies: A Comparative Study of Ketamine, Psilocybin, and Fluoxetine in a Chronic Stress Model - Domzalska M; Kwiatkowska J; Cichon I; Sokolowska E. (Research Square, 2025)

Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD - Mackenzie Hancock; Nicole Getz; Shambhu Prasad Adhikari (Open Science Framework, 2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases. - Heller NH; Barrett FS; Buchborn T; Collerton D; Dupuis D; Halberstadt AL; Jardri R; Noorani T; Preller KH; Taylor JP; Waters F; Winston BS; et al. (Schizophrenia bulletin, 2025)

Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders - M Loganathan; A Saravanakumar; P. Parthiban; G Anandharaj; S Gobika; D Dharshana; Mohamed Safir Ali (Journal of Pharma Insights and Research., 2025)

Harm reduction practises for users of psychedelic drugs: a scoping review. - Dutton C; North E; Chun Tie Y; Oliva J; Skeffington P (Harm reduction journal, 2025)

Psilocybin as a Treatment for Depression - Arif Ersegün Kahraman (University of Debrecen Electronic Archive, 2025)

An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109 - Bodhi Norton (PDXScholar (Portland State University), 2025)

Legal and Regulatory Barriers to Medical Psilocybin Use: An International Overview - Chweikh Mohamad (OSF Preprints, 2025)

Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment - University Hospital; Geneva (ClinicalTrials.gov, 2025)

Psilocybin-assisted psychotherapy in adults with depression - A literature review. - Dorczok MC; Mittmann G; Ettl T; Steiner-Hofbauer V (Progress in neuro-psychopharmacology & biological psychiatry, 2025)

Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior. - Richardson B; Inserra A; Pileggi M; Prud'Homme T; Bruno V; Wan-Yan-Chan D; Shareghi-Ghahreman I; Nasini S; Strand T; Leyton M; Sonenberg N; De Gregorio D; et al. (Progress in neuro-psychopharmacology & biological psychiatry, 2025)

Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review. - de Oliveira AL; de Oliveira DP; Dos Santos RG; Hallak JEC (Progress in neuro-psychopharmacology & biological psychiatry, 2025)

Understanding psilocybin mushrooms and aiding in setting standards for a burgeoning industry in Jamaica - Rupika Delgoda; Kimberley Foster; Isaac Morrison; Marshall Tyler; William Irvine; Lavonne Wilson; Babumon M. Thankappan; Shemar Daniel (Phytochemistry Letters, 2025)

Psychedelics and autobiographical memory - six open questions. - Kangaslampi S; Lietz M (Psychopharmacology, 2025)

Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD) - Johns Hopkins University (ClinicalTrials.gov, 2025)

Gestational LSD exposure in mouse rapidly reaches embryonic CSF and is associated with altered choroid plexus signaling, cerebral cortical development, and offspring behavior - Courtney Y; Anderson JM; Lagares-Linares C; Wenthur CJ; Lehtinen MK. (bioRxiv, 2025)

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude. - Chisamore N; Kaczmarek ES; Doyle Z; Johnson DE; Weiglein G; Meshkat S; Brudner RM; Blainey MG; Riva-Cambrin J; McIntyre RS; Rosenblat JD (Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2025)

Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway - Afrooghe Arya; Ahmadi Elham; Lesani Ali; Mehranjani Mahya Soleymani; Elahi Mohammad; Babaei Mohammadreza; Shayan Maryam; Shafaroodi Hamed; Jafari Razieh Mohammad; Foroumadi Alireza; Manavi Mohammad Amin; Dehpour Ahmad-Reza (Naunyn-Schmiedeberg's Archives of Pharmacology, 2025)

Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. - Borgogna NC; Owen T; Petrovitch D; Vaughn J; Johnson DAL; Pagano LA; Aita SL; Hill BD (Psychopharmacology, 2025)

Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice. - McGriff SA; Hecker JC; Maitland AD; Partilla JS; Baumann MH; Glatfelter GC (Psychopharmacology, 2025)

Correction to: Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. - Borgogna NC; Owen T; Petrovitch D; Vaughn J; Johnson DAL; Pagano LA; Aita SL; Hill BD (Psychopharmacology, 2025)

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. - Pellegrini L; Fineberg NA; O'Connor S; De Souza AMFLP; Godfrey K; Reed S; Peill J; Healy M; Rohani-Shukla C; Lee H; Carhart-Harris R; Robbins TW; et al. (Comprehensive psychiatry, 2025)

The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine. - Park D; Lee G; Lee WG; Kim B; Lee Y; Kim JW (Molecular psychiatry, 2025)

Treatment with LSD and psilocybin at the department of psychiatry at Frederiksberg Hospital in Denmark from 1960 to 1973: an analysis of 324 cases. - Larsen JK; Kølbæk P; Østergaard SD (Nordic journal of psychiatry, 2025)

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics. - Jain MK; Gumpper RH; Slocum ST; Schmitz GP; Madsen JS; Tummino TA; Suomivuori CM; Huang XP; Shub L; DiBerto JF; Kim K; DeLeon C; et al. (Neuron, 2025)

Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions. - Rosa I; Padula LP; Semeraro F; Marrangone C; Inserra A; De Risio L; Boffa M; Zoratto F; Borgi M; Guidotti R; Lorenzo GD; D'Addario C; et al. (Psychiatry research, 2025)

Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations. - Rajwani K; Jacobs E; Bruce L; Hokanson J; Almonte MT; Feroz F; Waldman E; Cheung K; Levy N; Savulescu J; Singh I; Yaden DB; et al. (The Lancet. Child & adolescent health, 2025)

US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022. - Montoy JCC; Wang RC; Coker AR; Smollin CG; Anderson BT (Journal of the American College of Emergency Physicians open, 2025)

Concomitant use of antidepressants and classic psychedelics: A scoping review. - Tap SC; Thomas K; Páleníček T; Stenbæk DS; Oliveira-Maia AJ; van Dalfsen JH; Schoevers RA (Journal of psychopharmacology (Oxford, England), 2025)

Serotonin 5-HT Receptor Signaling Analysis Reveals Psychedelic Biased Agonism. - Bonniwell EM; Alabdali R; Hennessey JJ; McKee JL; Cavalco NG; Lammers JC; Moore EJ; Franchini L; Orlandi C; McCorvy JD (ACS chemical neuroscience, 2025)

Dynamic myocardial injury and variable hallucination latency in poisoning: a molecularly confirmed case series from China. - He Z; Tang R; Feng M; Li X; Zhang C; Li J (Clinical toxicology (Philadelphia, Pa.), 2025)

Publisher Correction: Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors. - Shao LX; Liao C; Davoudian PA; Savalia NK; Jiang Q; Wojtasiewicz C; Tan D; Nothnagel JD; Liu RJ; Woodburn SC; Bilash OM; Kim H; et al. (Nature, 2025)

[Role of psychedelics in psychiatry: a true therapeutic revolution or a trend?]. - Sabé M; Seragnoli F; Penzenstadler L; Thorens G (La Revue du praticien, 2025)

3642 Down the rabbit hole: case reports of a hallucinogen-induced disorder of neuroperception - Anneliese McConnell; Wei He; Harry McConnell; Sandro Sprendei; Paul F. Sowman (Poster Abstracts, 2025)

B-302 Psychedelics and Dissociative Anesthetics: Concentrations in Suspected Impaired Driving Investigations, 2024 - Stephanie Marco (Clinical Chemistry, 2025)

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring. - Hatzipantelis CJ; Liu M; Love A; Leventhal SJ; Maera H; Viswanathan S; Avetisyan E; Belinsky L; Rangel MM; Jain NJ; Kelly M; Copeland C; et al. (Nature communications, 2025)

Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds - Pereira Galdino Taynah; Bisneto Antônio Braz de Medeiros; Pedro Marcelo da Silva; de Oliveira Lucas Cordeiro; Luz Mateus Araújo; de Lima Antônio Gilson Barbosa; Silva Suédina Maria de Lima; Fook Marcus Vinicius Lia (ACS Omega, 2025)

Ethical challenges in the therapeutic application of classical psychedelics for pediatric health conditions: A comprehensive review - Pinelopi Vlotinou; Konstantinos Christodoulou; Anna Tsiakiri; Foteini Christidi; Aspasia Serdari (Brazilian Journal of Science, 2025)

Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat - Egger; Klemens; Meling; Daniel; Polat; Firuze; Seifritz; Erich; Avram; Mihai; Scheidegger; Milan (Universität Zürich, ZORA, 2025)

Psychedelics Offer Healing and Ecological Remembrance for Marginalized Individuals Failed by U.S. Health Care - Nicole Torres (Ecopsychology, 2025)

Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review. - Caporuscio C; Poppe C; Gieselmann A; Repantis D (Psychological medicine, 2025)

Regional Specificity of the Cingulate Cortex Thickness Association with the Intensity of Psilocybin Experience: A Replication Study - Greguš D; Hlinka J; Tylš F; Viktorin V; Viktorinová M; Bravermanová A; Androvičová R; Andrashko V; Korčák J; Nikolič M; Adámek P; Beneš M; et al. (Research Square, 2025)

Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative review - Stefania Chiappini; Clara Cavallotto; Andrea Miuli; Giacomo d’Andrea; Alessio Mosca; Carlotta Marrangone; Rita Allegretti; Serena Panichella; Antonio d'Attilio; Giovanna Mammarella; Luca Persico; Alessia Santeusanio; et al. (Clinical Neuropsychopharmacology and Addiction, 2025)

Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism - Healing Advocacy Fund (ClinicalTrials.gov, 2025)

With great power comes great responsibility: Promise and caution in the new psychedelic renaissance - Matthew Halma; R. Levy; Joseph Varón (Brain Disorders, 2025)

Electrodynamics of the Psychedelic Experience - Hunt T. (Preprints.org, 2025)

Unterschiedliche Reaktionen und Enzyme in der Psilocybin- Biosynthese bei Inocybe- und Psilocybe -Pilzen - Tim Schäfer; Fabian Haun; Bernhard Rupp; Dirk Hoffmeister (Angewandte Chemie, 2025)

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study. - Knock E; Siefried KJ; Bedi G; Albert S; Day RO; Ezard N; Ross M; Liknaitzky P; Brett J (Addiction (Abingdon, England), 2025)

S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial - Benjamin R. Lewis (22279166); John Hendrick (22279169); Kevin Byrne (1610821); Madeleine Odette (22279172); Chaorong Wu (8444343); Eric L. Garland (4666660) (Figshare, 2025)

Psychedelics Relax Priors and Reshape Orbitofrontal Dynamics - Delgado-Sallent C; Ahmed SA; Khawaja-Lopez A; Lee BS; Senne R; Scott BB; Ramirez S. (bioRxiv, 2025)

Reappraisal of the hype and hope offered by psilocybin treatment of depression. - Beaglehole B; Manuel J (The New Zealand medical journal, 2025)

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US. - Calin A; Burlec AF; Mircea C; Macovei I; Hancianu M; Corciova A (Journal of clinical medicine, 2025)

PRoMiSS: Psilocybin and the Role of Music in Set and Setting - Johns Hopkins University (ClinicalTrials.gov, 2025)

Efficacy of Psychedelics Therapy Across Psychiatric Disorders: An Umbrella Review of Meta-Analyses - Lopez; Alissa A; Salloum; Ihsan; Lopez-Alvarenga; Juan C (ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley), 2025)

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia - Askey T; Allen-Ross D; Luzyanin D; Lasrado R; Gilmour G; Hunt SP; Tamagnini F; Ahmed M; Stephens GJ; Maiarú M. (bioRxiv, 2025)

Trauma under psychedelics: how psychoactive substances impact trauma processing - Ophir Netzer; Noa Magal; Yonatan Stern; Tzuk Polinsky; Raz Gross; Roee Admon; Roy Salomon (World Psychiatry, 2025)

The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial. - Maastricht University (ClinicalTrials.gov, 2025)

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia. - Sapienza J; Spangaro M; Comai S; Sabé M; La Torre J; Buonarroti M; Cavallaro R; Bosia M (International journal of molecular sciences, 2025)

Serotonin 5-HT2C Receptor SignalingAnalysis Reveals Psychedelic Biased Agonism - Emma M. Bonniwell (14267047); Rana Alabdali (22241286); Joseph J. Hennessey (22241289); John L. McKee (22179170); Natalie G. Cavalco (20388684); Josie C. Lammers (22241292); Ethan J. Moore (22241295); Luca Franchini (10578054); Cesare Orlandi (204175); John D. McCorvy (1416910) (Figshare, 2025)

Effective connectivity of the human claustrum: Triple networks, subcortical circuits, and psychedelic modulation - Masjedi NS; Razi A. (bioRxiv, 2025)

Mindset Over Molecule: Comparing Self-Transcendent and Mystical Experiences Across Recreational Psilocybin, MDMA, and Cannabis Use - Chwyl C; Spata A; Lucas W; Luoma JB. (Research Square, 2025)

Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy. - Bélanger A; Chang SL; Stephan JF; Moureaux F; Tapp D; Foxman R; Gagnon P; Hébert J; Farzin H; Dorval M (Healthcare (Basel, Switzerland), 2025)

The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting - Tereza Dleštíková (Psychoactives, 2025)

Therapeutic Divergence in 5-HTA Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome. - Kargbo RB (ACS medicinal chemistry letters, 2025)

Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression. - King's College London (ClinicalTrials.gov, 2025)

Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder - Alan K. Davis; Meghan DellaCrosse; Nathan D. Sepeda; Adam W. Levin; Mary P Cosimano; Hillary Shaub; Washington Taylor; Peter M. Gooch; Shoval Gilead; Skylar J. Gaughan; Stacey B. Armstrong; Frederick S. Barrett (Journal of Psychedelic Studies, 2025)

Blunted psychedelic drug effects in older adults - Aday JS; Carhart-Harris R; Boehnke KF. (PsyArXiv, 2025)

Blunted psychedelic drug effects in older adults - Jacob S. Aday; Robin Carhart-Harris; Kevin F. Boehnke (PsyArXiv, 2025)

Sample composition and HIV prevention indicator differences using physical vs virtual venue recruitment of men who have sex with men in San Francisco. - Chiu I; Tate M; Trujillo D; Suprasert B; Marr A; Arayasirikul S; Wilson EC; Raymond HF; McFarland W (American journal of epidemiology, 2025)

Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence. - Andrade FRT; Buchborn T; Thalheimer G; Meinhardt MW; Joca S; de Almeida RMM (Acta neuropsychiatrica, 2025)

Integrating Holistic Communication into Psychedelic-Assisted Therapies in Hospice and Palliative Care: An Approach Based on Peplau's Theory. - Mesquita Garcia AC; Teixeira F; Maia LO (Journal of holistic nursing: official journal of the American Holistic Nurses' Association, 2025)

Therapeutic Effects of Psychedelics and their Non-Hallucinogenic Analogs on Depressive-Like Behaviour - Kaylee Reid; Daniel Kot; Argel Aguilar-Valles (Carleton undergraduate journal of science., 2025)

The Psychedelic Reset: How Psychedelics May Reshape the Corticostriatal Circuit in Anorexia Nervosa - Maham Khurram (Carleton undergraduate journal of science., 2025)

Gregor Hasler: Three Guiding Questions - How do psychedelics shape the brain? How can they heal psychiatric disorders such as depression and PTSD? How can we ensure their safe and responsible use? - Gregor Hasler (Psychedelics., 2025)

Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care - Kerem Kemal Soylemez; Emma Marie de Boo; Aysil Susuzlu; Joanne Lusher (Psychoactives, 2025)

Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial - Khyber Medical University Peshawar (ClinicalTrials.gov, 2025)

Active Constituents of Psilocybin Mushroom Edibles. - van Breemen RB; Simchuk D; Fritzsche B; Huson D; Kuzdzal SA; Ferguson J (JAMA network open, 2025)

We may know why psilocybin helps treat mental health conditions - Chris Simms (The New Scientist, 2025)

Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report - M Mercier; Cédric Mabilais; Vasileios Chytas; Leonice Furtado; Federico Seragnoli; Albert Buchard; Tatiana Aboulafia Brakha; Gabriel Thorens; Daniele Zullino; Louise Penzenstadler (Psychoactives, 2025)

PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH - Anna Blazhkova; Magdalena Czaja; Hanna Sitka; Sven Solisch; Anna Susłow; Ewa Szczęsna (International Journal of Innovative Technologies in Social Science, 2025)

"Wood-lover paralysis": Describing a toxidrome with symptoms of weakness caused by some lignicolous "wood-loving" Psilocybe mushrooms. - Beck SA; Barlow C; Engel L; Barratt MJ (Toxicon: official journal of the International Society on Toxinology, 2025)

Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa. - McCoy K; Reed F; Conn K; Foldi CJ (Physiology & behavior, 2025)

Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review - Sudhakaran G; Chakraborty S; Aung San; Bharti SAK; Csaba V; Valan Arasu M; Namasivayam SKR; Arockiaraj J. (Curr Microbiol, 2025)

A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. - Palitsky R; Maples-Keller JL; Peacock C; Dunlop BW; Mletzko T; Grant GH; Raison CL; Chao S; Shub I; Mendelbaum-Kweller M; Smolyar L; Kaplan DM; et al. (Psychotherapy (Chicago, Ill.), 2025)

Quantitative natural language processing markers of psychoactive drug effects: A pre-registered systematic review. - Ahuja S; Zaher F; Palaniyappan L (Journal of psychopharmacology (Oxford, England), 2025)

Lifetime classic psychedelic use and headaches: A cross-sectional study. - Bjurenfalk Z; Cosmo A; Simonsson O; Ran C (Journal of psychopharmacology (Oxford, England), 2025)

Psilocybin biosynthesis enhancement through gene source optimization. - Keller MR; McKinney MG; Sen AK; Guagliardo FG; Hellwarth EB; Islam KN; Kaplan NA; Gibbons WJ; Kemmerly GE; Meers C; Wang X; Jones JA (Metabolic engineering, 2025)

Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review. - Estric C; Duron T; Kabani S; Lopez-Castroman J (Journal of psychopharmacology (Oxford, England), 2025)

Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa - McCoy K; Reed F; Conn K; Foldi CJ. (Physiology & behavior, 2025)

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium. - Vella Y; Syrová K; Petrušková A; Koutrouli I; Kútna V; Pala J; Šíchová K; Nikolič M; Mazoch V; Jurok R; Kuchař M; Bendová Z; et al. (Journal of psychopharmacology (Oxford, England), 2025)

Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire. - Andersen KAA; Holmøy B; Kvam TM; Johnson MW (Journal of psychiatric research, 2025)

“Wood-lover paralysis”: Describing a toxidrome with symptoms of weakness caused by some lignicolous “wood-loving” Psilocybe mushrooms - Beck SA; Barlow C; Engel L; Barratt MJ. (Toxicon, 2025)

Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms. - Blanton AM; Parikh P; Zhou S; Mohamed M; Ufret-Vincenty RL; Mancini R (American journal of ophthalmology case reports, 2025)

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression. - Brudner RM; Kaczmarek E; Blainey MG; Schulz-Quach C; Meshkat S; Doyle Z; Lipsitz O; Offman H; Sethi R; Weiglein G; McIntyre RS; Rosenblat JD (Journal of psychopharmacology (Oxford, England), 2025)

Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats - Vejmola Čestmír; Šíchová Klára; Syrová Kateřina; Janečková Lucie; Koudelka Vlastimil; Tesař Michael; Nikolič Marek; Viktorinová Michaela; Tylš Filip; Korčák Jakub; Viktorin Vojtěch; Kelemen Eduard; et al. (Biological Psychiatry Global Open Science, 2025)

Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action. - Miller EA; Capone C; Eaton E; Swift RM; Haass-Koffler CL (CNS drugs, 2025)

Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics. - Swieczkowski D; Kwaśny A; Ciurkowska P; Pruc M; Szarpak L; Cubała WJ (Journal of psychopharmacology (Oxford, England), 2025)

A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction. - Glenn DL; Choi SH; Zimmerman RS (Journal of psychopharmacology (Oxford, England), 2025)

Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers. - Nadeem Z; Parker S; McGovern H; Sebben B; Oestreich LK (The Australian and New Zealand journal of psychiatry, 2025)

Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation. - Cherup NP; Finan PH (The journal of pain, 2025)

Psychedelic use in Poland: prevalence, correlates and social attitudes. - Holas P; Kamińska J (Postepy psychiatrii neurologii, 2025)

Severe Rhabdomyolysis With Stage 3 Acute Kidney Injury After Ayahuasca Use Managed Without Renal Replacement Therapy: A Case Report. - Kermanshah A; Stapleton M; Mauriello CM; Cobas M; Cordoba Torres IT (Cureus, 2025)

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. - Lewis BR; Hendrick J; Byrne K; Odette M; Wu C; Garland EL (PLoS medicine, 2025)

A lexicon for psychedelic research and treatment - David Nutt; David Erritzøe; Anne Katrin Schlag; David Luke; Deborah C. Mash; Hiroyuki Uchida; Jacob S. Aday; James Rucker; Liliana Galindo; Mark Sweeney; Matthew X. Lowe; Oliver Davis; et al. (Drug Science Policy and Law, 2025)

„Wir haben gezeigt, dass die Psilocybin-unterstützte Psychotherapie wirksam ist“ - Müller Thomas (InFo Neurologie + Psychiatrie, 2025)

Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury. - Plummer Z; Allen J; Brand J; Mayo LM; Shultz SR; Christie BR (Progress in neuro-psychopharmacology & biological psychiatry, 2025)

An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions. - Askariyan K; Joghataei MT; Dehghan S; Nohesara S; Riahi Pour L; Mohammadi MH; Ahmadirad N (Progress in neuro-psychopharmacology & biological psychiatry, 2025)

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis. - Avanceña ALV; Vuong L; Kahn JG; Marseille E (Translational psychiatry, 2025)

Freedom of Recreation: A Critique of the Prohibition, Decriminalization, and Legal Regulation of Psychedelics for Recreational Use - Jason K. Day; Michael Th. Grooff (Contemporary Drug Problems, 2025)

Unsupervised Extractive Summarization of Psychedelic User Experience Reports - Islam S; Salam S; Hasan MN. (medRxiv, 2025)

Psychedelic minimalism: the case against music in psychedelic therapy settings - Samir A Nader (Frontiers in Psychiatry, 2025)

Psilocybin: Systematic review of its use in the treatment of depression - Andres-Olivera P; de la Iglesia J; Dominguez-Alvarez E; Soto’Gonzalez P; Rodriguez C; Munaiz-Cossio C; Gonzalez-Bolaños R; Brito-Rey R; Marín-Lorenzo C; Arribas-Simon B. (European psychiatry: the journal of the Association of European Psychiatrists, 2025)

“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy - Elise C. Tarbi; Skye A. Miner; Kabir Nigam; Zachary Sager; Justin J. Sanders; Michael Ljuslin; Benjamin Guérin; Kimberly Roddy; James A. Tulsky; Manish Agrawal; Yvan Beaussant (Psychedelic Medicine, 2025)

Context-dependent structurally informed effective connectivity under psilocybin - Greaves MD; Barta T; Novelli L; Stoliker D; Razi A. (bioRxiv, 2025)

Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion. - Zeifman R; Danias G; Agin-Liebes G; Pagni B; Kettner H; Bhat V; Ross S; Erritzoe D; Carhart-Harris R (Research square, 2025)

Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2025)

Psychedelics and the Serotonin Hypothesis of Eating Disorders. - Bilenker D; Avena NM (Brain sciences, 2025)

Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics? - Albert Garcia-Romeu (NPP-Digital Psychiatry and Neuroscience, 2025)

Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2025)

Effects of Psilocybin in Post-Treatment Lyme Disease - Johns Hopkins University (ClinicalTrials.gov, 2025)

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder - COMPASS Pathways (ClinicalTrials.gov, 2025)

Attitudes Toward Psychedelic-Assisted Therapies for Cancer-Related Psychosocial Symptoms: A Multi- Stakeholder Analysis - Schuman HD; Deleemans JM; Nguyen T; Savard C; Mina R; Carlson LE. (Research Square, 2025)

Serotonin and psilocybin activate 5-HT receptors to suppress cortical signaling through the claustrum. - Madden MB; Schaefgen C; Vedak B; Kwon J; Pedra KSD; Sheats SH; Puche AC; Wolff SBE; Mathur BN (Nature communications, 2025)

Selective Phosphorylation of Phenols and Benzenediols by the Kinase PsiK and Variants Thereof. - Kim A; Morato NM; Saha P; Eyimegwu PN; Niyaz AA; Huang R; Cooks RG; Phelan RM; Lewis JC (Angewandte Chemie (International ed. in English), 2025)

Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource - Singleton SP; Sevchik BL; Lahey A; Cuijpers P; Harrer M; Jones MT; Nayak SM; Strain EC; Vandekar SN; Dworkin RH; Scott JC; Satterthwaite TD. (medRxiv, 2025)

Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action. - Repple J; Bayas M; Möser C; Kobayashi NF; Reif A (Biological psychiatry, 2025)

Psychedelic researchers’ own experiences of psychedelic substances, their link to opinions of psychedelics, and reflections on positionality - Jussi Jylkkä; Aila Mustamo (Psychopharmacology, 2025)

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment. - Silczuk A; Madejek RJ; Koweszko T; Mularczyk-Tomczewska P; Adamska E; Gujski M; Szulc A (Medical science monitor: international medical journal of experimental and clinical research, 2025)

Psychedelics and Headache Disorders: an Update. - Im JJH; Sandoe CH (Current neurology and neuroscience reports, 2025)

Intersecting Psychedelic Pharmacology and Gut-Brain Axis Signaling in Neurodegenerative Disorders - Harsha S. Krishna (JUNIOR RESEARCHERS, 2025)

The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin - Zhang Miyuan; Zhai Haojiang; Yang Longwei; Li Haohong; Wang Xiaohui (ACS Pharmacology & Translational Science, 2025)

The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal. - Fernández-Borkel T; Borkel LF; Rojas-Hernández J; Hernández-Álvarez E; Quintana-Hernández DJ; Ponti LG; Henríquez-Hernández LA (ACS pharmacology & translational science, 2025)

The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression? - Trevor R. Norman (Exploration of neuroscience, 2025)

Substance Abuse and Cognitive Decline: The Critical Role of Tau Protein as a Potential Biomarker. - Rebolledo-Pérez L; Hernández-Bello J; Martínez-Ramos A; Castañeda-Arellano R; Fernández-Quezada D; Sandoval-García F; Aguilar-García IG (International journal of molecular sciences, 2025)

Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks - Jiang Q; Shao L; Yao S; Savalia NK; Gilbert AD; Davoudian PA; Nothnagel JD; Tian G; Hung TS; Lai H; Beier KT; Zeng H; et al. (bioRxiv, 2025)

Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications. - Wang X; Jun F; Lin C; Wang X (ACS chemical neuroscience, 2025)

Psychedelics, Spirituality, and Fundamentalism: A Brain Network Approach to Cognitive Flexibility and Rigidity. - Yang A; Lv X; Wang H; Wang X (ACS chemical neuroscience, 2025)

Latent Classes of Lifetime Use of Seven Hallucinogens in the United States. - Meacham MC; Mian MN; Wang RC; Coker AR; Anderson BT; Montoy JCC (Journal of psychoactive drugs, 2025)

Interventions to support spirituality among adults with cancer: a scoping review. - Miller M; Meyers M; Krainak K; Lewis SP (Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, 2025)

544. MOLECULAR AND CELLULAR MECHANISMS OF THE LONG-LASTING EFFECTS OF PSYCHEDELICS AND THEIR NON-HALLUCINOGENIC DERIVATIVES - Argel Aguilar-Valles; Dhiral Kot; Victor Lewis; Gianfilippo Coppola (The International Journal of Neuropsychopharmacology, 2025)

670. CAN WE RE-MEDICALISE THE PSYCHEDELIC EXPERIENCE? - Guy M. Goodwin (The International Journal of Neuropsychopharmacology, 2025)

Psychedelics as treatment of alcohol use disorders: insights from preclinical models and comparison of the different psychedelics psilocybin, LSD and ketamine - Mickaël Naassïla (Neuroscience, 2025)

519. PSILOCYBIN ASSISTED PSYCHOTHERAPY FOR OBSESSIVE COMPULSIVE DISORDER, BODY DYSMORPHIC DISORDER, AND ANOREXIA NERVOSA: STUDY PROTOCOL - N Acevdo; D Castle; S Rossell (The international journal of neuropsychopharmacology, 2025)

631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS - G Martinotti; C Cavallotto; G D'Andrea; A D'Attilio; G Mammarella; F Zoratto; M Pettorruso (The international journal of neuropsychopharmacology, 2025)

317. PSILOCYBIN DOES NOT INDUCE CONDITIONED PLACE PREFERENCE, BUT MODIFIES BEHAVIORAL PATTERNS IN SPRAGUE-DAWLEY RATS - V Bruno; B Richardson; M Lopez-Canul; T Marcourakis; R Camarini; G Gobbi (The international journal of neuropsychopharmacology, 2025)

164. PSILOCYBIN DURING THE POSTPARTUM PERIOD INDUCES LONG-LASTING ADVERSE EFFECTS IN BOTH MOTHERS AND OFFSPRING - C Hatzipantelis; D Olson; D Stolzenberg (The international journal of neuropsychopharmacology, 2025)

620. IDENTIFICATION OF BLOOD BIOMARKERS OF PSILOCYBIN-ASSISTED THERAPY TREATMENT RESPONSE FOR GENERALISED ANXIETY DISORDER - A Gibbons; P Liknaitzky; S Sundram (The international journal of neuropsychopharmacology, 2025)

426. THE MGLUR2/3 ANTAGONIST ENHANCES THE BEHAVIORAL AND CELLULAR ANTIDEPRESSANT-LIKE EFFECTS OF PSILOCYBIN AND SCOPOLAMINE - Y Babii; C-S Barbara; D Bederska-Łojewska; B Szewczyk; A Pałucha-Poniewiera; K Gołembiowska; A Pilc (The international journal of neuropsychopharmacology, 2025)

694. INVESTIGATING THE POTENTIAL OF PSILOCYBIN FOR COMPULSIVE EATING IN A RAT MODEL OF BINGE EATING - N Fabila; N P Manaph; V Rudkowsky; D Sketriene; Y Li; R Anversa; L Walker; A Reichelt; C Foldi; M Menden; R Brown (The international journal of neuropsychopharmacology, 2025)

363. DIFFERENTIAL EFFECTS OF PSILOCYBIN AND LISURIDE ON SEROTONIN AND DOPAMINE NEURONAL ACTIVITY AND BEHAVIOR - B Richardson; M Pileggi; T Prud’Homme; D Wan-Yan-Chan; I Shareghi-Ghahreman; S Nasini; V Bruno; T Strand; M Leyton; N Sonenberg; D De Gregorio; J Sprouse; et al. (The international journal of neuropsychopharmacology, 2025)

229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL - S Meikle; O Carter; P Liknaitzky; L Johansen; R Iyer; N Strauss; M Williams; D Castle; S Rossell (The international journal of neuropsychopharmacology, 2025)

205. SYNERGISTIC BEHAVIORAL AND NEUROPLASTIC EFFECTS OF PSILOCYBIN-NMDAR MODULATOR ADMINISTRATION - B Lerer; T Ben Tal; I Pogodin; A Botvinnik; T Lifschytz; U Heresco-Levy (The international journal of neuropsychopharmacology, 2025)

564. TOWARD AN UNDERSTANDING OF THE THERAPEUTICALLY RELEVANT MECHANISMS OF PSILOCYBIN FOR ANOREXIA NERVOSA - C Foldi (The international journal of neuropsychopharmacology, 2025)

476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS - T Renoir; J Gattuso; B Bezcioglu; G Kong; M Ekwudo; C Wilson; N Kleditzsch; A Kamal; J Hendey; C Gubert; A Hannan (The international journal of neuropsychopharmacology, 2025)